Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | GRNA | Common Stock | Other | -207K | -100% | 0 | Jul 24, 2023 | See Footnote | F1, F2 |
Michael Ruettgers is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Id | Content |
---|---|
F1 | This Form 4 reports securities contributed by the Reporting Person in connection with the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2023, by and among GreenLight Biosciences Holdings, PBC, SW ParentCo, Inc. ("Parent"), and SW MergerCo, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), to Merger Sub in exchange for shares of Series A-2 Preferred Stock, par value $0.001 per share, of Parent pursuant to a Contribution and Exchange Agreement, dated May 29, 2016 (the "Contribution and Exchange Agreement"), between Parent and the Michael Ruettgers Revocable Trust. The price used to calculate the value of each share of Series A-2 Preferred Stock for purposes of the exchange was $0.40 per share, as determined pursuant to the terms of the Contribution and Exchange Agreement. |
F2 | Represents shares held by the Michael Ruettgers Revocable Trust as amended and restated. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |